AlphaMind Brands Inc is entering the functional mushrooms market.
MindMed Launches Project Lucy Focused On LSD Experiential Therapy For Anxiety Disorders
MindMed has high hopes for its new LSD-based anxiety therapy.
TSI EDITOR |
2020-06-04
Dr. Devon Christie, MD CCFP RTC IFMCP, joins Numinus as Medical Director
Numinus adds to its management team.
TSI EDITOR |
2020-06-03
MindMed Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD
MindMed's Microdosing Division is expanding its ADHD clinical trial.
TSI EDITOR |
2020-06-02
Champignon Announces Voluntary Share Lock-Up; Retains Gold Standard Media, LLC for Financial Marketing
Certain shareholders have agreed to a voluntary resale restriction that covers 17.8 million shares.
TSI EDITOR |
2020-05-29
Numinus Announces 2020 Operational Plans to Scale
Newly-listed Numinus Wellness provides a corporate update.
TSI EDITOR |
2020-05-28
MindMed Adds MDMA for Development of Next-Gen Psychedelic Therapies
MindMed further expands R&D collaboration with University Hospital Basel's Liechti Lab with plans to develop next-gen psychedelic therapies combining LSD and MDMA.
TSI EDITOR |
2020-05-27
Numinus Takes Off On Initial Day Of Trading
Numinus Wellness is a new psychedelics stock that is up over 300% on its initial day of trading.
TSI EDITOR |
2020-05-20
Latest Stories
NEW BULL MARKET ALERT
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now